v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Operating expenses:        
Research and development $ 2,958 $ 4,659 $ 8,441 $ 7,568
General and administrative 6,642 12,458 16,864 14,558
Settlement expense       21,366
Reimbursement of expenses from Relief Therapeutics       (771)
Total operating expenses 9,600 17,117 25,305 42,721
Loss from operations (9,600) (17,117) (25,305) (42,721)
Other (income) expenses:        
Gain on extinguishment of debt       (121)
Interest income (23)   (23)  
Interest expense   5 3 10
Change in fair value of warrant liability (116) (17,359) (273) (17,359)
Change in fair value of Earnout Cash liability (2,479) 355 (4,582) 355
Total other (income) expenses (2,618) (16,999) (4,875) (17,115)
Net loss (6,982) (118) (20,430) (25,606)
Deemed dividend   (255,822)   (255,822)
Net loss attributable to common stockholders $ (6,982) $ (255,940) $ (20,430) $ (281,428)
Net loss per share:        
Basic $ (0.11)   $ (0.32) $ (0.66)
Diluted (0.11) $ (0.41) (0.32) (1.10)
Net loss per share attributable to common stockholders:        
Basic (0.11) (6.13) (0.32) (7.27)
Diluted $ (0.11) $ (6.43) $ (0.32) $ (7.63)
Weighted average common shares outstanding:        
Basic 65,732,343 41,727,480 64,348,966 38,709,614
Diluted 65,732,343 42,494,386 64,348,966 39,140,261

Source